Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
RISK OF THYROID C-CELL TUMORS
Bydureon (exenatide extended-release) for injectable suspension is a GLP-1 receptor agonist supplied as a sterile powder to be suspended in diluent and administered by subcutaneous injection. Exenatide is a 39-amino acid synthetic peptide amide with an empirical formula of C184H282N50O60S and a molecular weight of 4186.6 Daltons. The amino acid sequence for exenatide is shown below.
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-IleGlu- Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Bydureon is a white to off-white powder that is available in a dosage strength of 2 mg exenatide per vial or per pen. Exenatide is incorporated in an extended-release microsphere formulation containing the 50:50 poly(D,L-lactide-co-glycolide) polymer (37.2 mg per dose) along with sucrose (0.8 mg per dose). The powder must be suspended in the diluent prior to injection.
The diluent for the Bydureon vial is supplied in a prefilled syringe within each single-dose tray. The diluent for the Bydureon Pen is contained within each single-dose pen. Each configuration contains sufficient diluent to deliver 0.65 mL. The diluent is a clear, colorless to pale-yellow solution composed of carboxymethylcellulose sodium (19 mg), polysorbate 20 (0.63 mg), sodium phosphate monobasic monohydrate (0.61 mg), sodium phosphate dibasic heptahydrate (0.51 mg), sodium chloride (4.1 mg), and water for injection. Sodium hydroxide may be added during manufacture of Bydureon Pen for pH adjustment.
BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
For extended-release injectable suspension available as a:
BYDUREON (exenatide) for extended-release injectable suspension is supplied as:
BYDUREON Pen supplied in cartons that contain four single-dose pens and one spare needle (NDC 0310-6530-04). Each single-dose pen contains:
Do not substitute needles or any other components provided with BYDUREON.
Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850. By: Resilience US, Inc. West Chester, OH 45071. Revised: May 2025
The following serious adverse reactions are described below or elsewhere in the Prescribing Information:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data presented below are derived from six comparator-controlled trials of BYDUREON in adult patients who entered the studies not achieving adequate glycemic control on their current therapy [see Clinical Studies].
The safety of BYDUREON in pediatric patients age 10 to less than 18 years with type 2 diabetes was similar to that observed in adults (Trial 8) [see Clinical Studies].
Tables 1 and 2 summarize adverse reactions in adults with type 2 diabetes mellitus with an incidence ≥5% reported in the six comparator-controlled 24- to 30-week trials of BYDUREON used as monotherapy or as add-on to metformin, a sulfonylurea, a thiazolidinedione, or combination of these oral antidiabetic agents. Nausea was a common adverse reaction associated with initiation of treatment with BYDUREON and usually decreased over time.
Table 1: Adverse Reactions Reported in ≥5% of BYDUREON-Treated Adult Patients with Type 2 Diabetes Mellitus in Monotherapy Trial (Trial 1)
| 26-Week Monotherapy Trial | ||||
| BYDUREON 2 mg N = 248 % |
Sitagliptin 100 mg N = 163 % |
Pioglitazone 30-45 mg (mean dose 40 mg) N = 163 % |
Metformin 1000-2500 mg (mean dose 2077 mg) N = 246 % |
|
| Nausea | 11.3 | 3.7 | 4.3 | 6.9 |
| Diarrhea | 10.9 | 5.5 | 3.7 | 12.6 |
| Injection-site nodule* | 10.5 | 6.7 | 3.7 | 10.2 |
| Constipation | 8.5 | 2.5 | 1.8 | 3.3 |
| Headache | 8.1 | 9.2 | 8.0 | 12.2 |
| Dyspepsia | 7.3 | 1.8 | 4.9 | 3.3 |
| N = number of intent-to-treat patients; Percentages are based on the number of intent-to-treat patients in each treatment group. * Patients in the sitagliptin, pioglitazone, and metformin treatment groups received weekly placebo injections. |
||||
Table 2: Adverse Reactions Reported in ≥5% of BYDUREON-Treated Patients with Type 2 Diabetes Mellitus in 24-to 30-Week Add-On Combination Therapy Trials
| 26-Week Add-On to Metformin Trial (Trial 2) | |||
| BYDUREON 2 mg (N = 160) % |
Sitagliptin 100 mg (N = 166) % |
Pioglitazone 45 mg (N = 165) % |
|
| Nausea | 24.4 | 9.6 | 4.8 |
| Diarrhea | 20.0 | 9.6 | 7.3 |
| Vomiting | 11.3 | 2.4 | 3.0 |
| Headache | 9.4 | 9.0 | 5.5 |
| Constipation | 6.3 | 3.6 | 1.2 |
| Fatigue | 5.6 | 0.6 | 3.0 |
| Dyspepsia | 5.0 | 3.6 | 2.4 |
| Decreased appetite | 5.0 | 1.2 | 0.0 |
| Injection-site pruritus* | 5.0 | 4.8 | 1.2 |
| 26-Week Add-On to Metformin or Metformin + Sulfonylurea Trial (Trial 3) | |||
| BYDUREON 2 mg (N = 233) % |
Insulin Glargine Titrated (N = 223) % |
||
| Nausea | 12.9 | 1.3 | |
| Headache | 9.9 | 7.6 | |
| Diarrhea | 9.4 | 4.0 | |
| Injection-site nodule | 6.0 | 0.0 | |
| 30-Week Monotherapy or as Add-On to Metformin, a Sulfonylurea, a Thiazolidinedione, or Combination of Oral Agents Trial (Trial 9) | |||
| BYDUREON 2 mg once weekly (N = 148) % |
BYETTA 10 mcg twice daily (N = 145) % |
||
| Nausea | 27.0 | 33.8 | |
| Diarrhea | 16.2 | 12.4 | |
| Vomiting | 10.8 | 18.6 | |
| Injection-site pruritus | 18.2 | 1.4 | |
| Constipation | 10.1 | 6.2 | |
| Gastroenteritis viral | 8.8 | 5.5 | |
| Gastroesophageal reflux disease | 7.4 | 4.1 | |
| Dyspepsia | 7.4 | 2.1 | |
| Injection-site erythema | 7.4 | 0.0 | |
| Fatigue | 6.1 | 3.4 | |
| Headache | 6.1 | 4.8 | |
| Injection-site hematoma | 5.4 | 11.0 | |
| 24-Week Monotherapy or as Add-On to Metformin, a Sulfonylurea, a Thiazolidinedione, or Combination of Oral Agents Trial (Trial 4) | |||
| BYDUREON 2 mg (N = 129) % |
BYETTA 10 mcg (N = 123) % |
||
| Nausea | 14.0 | 35.0 | |
| Diarrhea | 9.3 | 4.1 | |
| Injection-site erythema | 5.4 | 2.4 | |
| 26-Week Add-On to Metformin, a Sulfonylurea, Metformin + Sulfonylurea, or Metformin + Pioglitazone Trial (Trial 5) | |||
| BYDUREON 2 mg (N = 461) % |
|||
| Injection-site nodule | 10.4 | ||
| Nausea | 9.3 | ||
| Diarrhea | 6.1 | ||
| N = number of intent-to-treat patients; Percentages are based on the number of intent-to-treat patients in each treatment group. * Patients in the sitagliptin, pioglitazone, and metformin treatment groups received weekly placebo injections. |
|||
The incidence of withdrawal due to adverse reactions in adults with type 2 diabetes mellitus was 4.1% (N=57) for BYDUREON-treated patients, 4.9% (N=13) for BYETTA-treated patients, and 2.9% (N=46) for other comparator-treated patients in the six comparator-controlled 24- to 30-week trials. The most common classes of adverse reactions (0.5%) leading to withdrawal for BYDUREON-treated patients were, Gastrointestinal Disorders 1.6% (N=22) versus 4.1% (N=11) for BYETTA and 1.9% (N=30) for other comparators, and Administration Site Conditions 0.8% (N=11) versus 0.0% for BYETTA and 0.2% (N=3) for other comparators.
The most frequent adverse reactions within each of these respective classes were, nausea 0.4% (N=6) for BYDUREON versus 1.5% (N=4) for BYETTA and 0.8% (N=12) for other comparators, and injection-site nodule, 0.4% (N=6) for BYDUREON versus 0.0% for BYETTA and 0.0% for other comparators.
Table 3 summarizes the incidence of hypoglycemia (defined as the presence of symptoms of hypoglycemia with a concomitant glucose <54 mg/dL and the ability to self-treat) in the six comparator-controlled 24- to 30-week trials of BYDUREON in adults with type 2 diabetes mellitus. BYDUREON was used as monotherapy or as add-on to metformin, a sulfonylurea, a thiazolidinedione, or combination of these oral antidiabetic agents.
Table 3: Incidence (% of Subjects) of Hypoglycemia* in Clinical Trials in Adult Patients with Type 2 Diabetes Mellitus
| 26-Week Monotherapy Trial (Trial 1) | |
| BYDUREON 2 mg (N = 248) | 2.0% |
| Sitagliptin 100 mg (N = 163) | 0.0% |
| Pioglitazone 30-45 (mean dose 40) mg (N = 163) | 0.0% |
| Metformin 1000-2500 (mean dose 2077) mg (N = 246) | 0.0% |
| 26-Week Add-On to Metformin Trial (Trial 2) | |
| BYDUREON 2 mg (N = 160) | 1.3% |
| Sitagliptin 100 mg (N = 166) | 3.0% |
| Pioglitazone 45 mg (N = 165) | 1.2% |
| 26-Week Add-On to Metformin or Metformin + Sulfonylurea Trial (Trial 3) | |
| With Concomitant Sulfonylurea Use (N = 136) | |
| BYDUREON 2 mg (N = 70) | 20.0% |
| Titrated Insulin Glargine (N = 66) | 43.9% |
| Without Concomitant Sulfonylurea Use (N = 320) | |
| BYDUREON 2 mg (N = 163) | 3.7% |
| Titrated Insulin Glargine†(N = 157) | 19.1% |
| 24-Week Monotherapy or Add-On to Metformin, a Sulfonylurea, a Thiazolidinedione, or | |
| Combination of Oral Agents Trial (Trial 4) | |
| With Concomitant Sulfonylurea Use (N = 74) | |
| BYDUREON 2 mg (N = 40) | 12.5% |
| BYETTA 10 mcg (N = 34) | 11.8% |
| Without Concomitant Sulfonylurea Use (N = 178) | |
| BYDUREON 2 mg (N = 89) | 0.0% |
| BYETTA 10 mcg (N = 89) | 0.0% |
| 30-Week Monotherapy or Add-On to Metformin, a Sulfonylurea, a Thiazolidinedione, or | |
| Combination of Oral Agents Trial (Trial 9) | |
| With Concomitant Sulfonylurea Use (N = 107) | |
| BYDUREON 2 mg (N = 55) | 14.5% |
| BYETTA 10 mcg (N = 52) | 15.4% |
| Without Concomitant Sulfonylurea Use (N = 186) | |
| BYDUREON 2 mg (N = 93) | 0.0% |
| BYETTA 10 mcg (N = 93) | 1.1% |
| 26-Week as Add-On to Metformin, a Sulfonylurea, Metformin + Sulfonylurea,or Metformin + | |
| Pioglitazone Trial (Trial 5) | |
| With Concomitant Sulfonylurea Use (N = 590) | |
| BYDUREON 2 mg (N = 294) | 15.3% |
| Without Concomitant Sulfonylurea Use (N = 321) | |
| BYDUREON 2 mg (N = 167) | 3.6% |
| N = number of intent-to-treat (ITT) patients; Percentages were based on the number of ITT patients in each treatment group. * Reported event that has symptoms consistent with hypoglycemia with a concomitant glucose <54 mg/dL and the patient was able to self-treat. † Insulin glargine was dosed to a target fasting glucose concentration of 72 to 100 mg/dL. The mean dose of insulin glargine was 10 units/day at baseline and 31 units/day at endpoint. |
|
In the 24-week pediatric placebo-controlled clinical trial (Trial 8) [see Clinical Studies], 2 (3.4%) of BYDUREON-treated patients with type 2 diabetes had hypoglycemia with a blood glucose <54 mg/dL with or without symptoms and 1 (1.7%) had severe hypoglycemia (defined as an episode with severe cognitive impairment requiring external assistance for recovery).
In five comparator-controlled 24- to 30-week trials in adults, injection-site reactions were observed more frequently in BYDUREON-treated patients (17%) than in BYETTA-treated patients (13%), titrated insulin glargine-treated patients (1.8%), or placebo-treated patients (sitagliptin (11%), pioglitazone (6%), and metformin (13%) treatment groups). One percent of BYDUREON-treated patients withdrew due to injection-site adverse reactions (injection-site mass, injection-site nodule, injection-site pruritus, and injection-site reaction).
In a separate 15-week study of BYDUREON in adults in which information on nodules were collected and analyzed, 24 out of 31 subjects (77%) experienced at least 1 injection-site nodule during treatment; 2 subjects (7%) reported accompanying localized symptoms. The mean duration of events was 27 days.
Injection site reactions for BYDUREON-treated patients were more commonly observed in those who were antibody-positive (anti-exenatide antibodies) (14%) compared with those who were antibody-negative (3%) [see CLINICAL PHARMACOLOGY].
Increases in heart rate from baseline ranging from 1.5 to 4.5 beats per minute have been observed in BYDUREON-treated patients in comparator-controlled clinical trials in adults.
In the EXSCEL trial [see Clinical Studies], 1.9% of BYDUREON-treated patients and 1.4% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis.
The following adverse reactions were also reported in three 30-week controlled trials (in adults with type 2 diabetes mellitus) of BYETTA (N=963) add-on to metformin and/or sulfonylurea, with an incidence of ≥1% and reported more frequently than with placebo: feeling jittery (9% BYETTA, 4% placebo), dizziness (9% BYETTA, 6% placebo), asthenia (4% BYETTA, 2% placebo), and hyperhidrosis (3% BYETTA, 1% placebo).
The following additional adverse reactions have been reported during post-approval use of BYDUREON or other formulations of exenatide. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood: Drug-induced thrombocytopenia.
Drug Interactions: Increased international normalized ratio (INR), sometimes associated with bleeding, with concomitant warfarin use [see DRUG INTERACTIONS].
Gastrointestinal: Nausea, vomiting, and/or diarrhea resulting in dehydration; abdominal distension, abdominal pain, eructation, constipation, flatulence, ileus, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death.
Hepatobiliary: Cholecystitis, cholelithiasis requiring cholecystectomy.
Hypersensitivity: Injection-site reactions (e.g., abscess, cellulitis, and necrosis, with or without subcutaneous nodules), generalized pruritus and/or urticaria, macular or papular rash, angioedema; anaphylactic reaction.
Neurologic: Dysgeusia, somnolence, dysesthesia.
Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.
Renal: Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant and kidney transplant dysfunction.
Skin and Subcutaneous Tissue Disorders: Alopecia.
Table 4: Clinically Relevant Interactions with BYDUREON
| Concomitant Use of Insulin Secretagogues or Insulin | |
| Clinical Impact | Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]. |
| Intervention | When initiating BYDUREON, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia. |
| Warfarin | |
| Clinical Impact | BYDUREON has not been studied with warfarin. However, in a drug interaction study, BYETTA did not have a significant effect on INR [see CLINICAL PHARMACOLOGY]. There have been postmarketing reports for exenatide of increased INR with concomitant use of warfarin, sometimes associated with bleeding [see ADVERSE REACTIONS]. |
| Intervention | In patients taking warfarin, the INR should be monitored more frequently after initiating BYDUREON. Once a stable INR has been documented, the INR can be monitored at the intervals recommended for patients taking warfarin. |
| Orally Administered Drugs (e.g., acetaminophen) | |
| Clinical Impact | Exenatide slows gastric emptying. Therefore, BYDUREON has the potential to reduce the rate of absorption of orally administered drugs [see CLINICAL PHARMACOLOGY]. |
| Intervention | Use caution when administering oral medications with BYDUREON where a slower rate of oral absorption may be clinically meaningful. |
Included as part of the PRECAUTIONS section.
In both genders of rats, exenatide extended-release caused a dose-related and treatment-duration– dependent increase in the incidence of thyroid C-cell tumors (adenomas and/or carcinomas) at clinically relevant exposures compared to controls [see Nonclinical Toxicology]. A statistically significant increase in malignant thyroid C-cell carcinomas was observed in female rats receiving exenatide extended-release at 25-times clinical exposure compared to controls and higher incidences were noted in males above controls in all treated groups at ≥2-times clinical exposure. The potential of exenatide extended-release to induce C-cell tumors in mice has not been evaluated. Other glucagon-like peptide-1 (GLP-1) receptor agonists have also induced thyroid C-cell adenomas and carcinomas in male and female mice and rats at clinically relevant exposures. It is unknown whether BYDUREON will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined.
Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.
BYDUREON is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk of MTC with the use of BYDUREON and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with BYDUREON. Such monitoring may increase the risk of unnecessary procedures, due to the low specificity of serum calcitonin testing for MTC and a high background incidence of thyroid disease. Significantly elevated serum calcitonin may indicate MTC and patients with MTC usually have values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including BYDUREON [see ADVERSE REACTIONS]. After initiation of BYDUREON, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue BYDUREON and initiate appropriate management.
Patients receiving BYDUREON in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see ADVERSE REACTIONS and DRUG INTERACTIONS].
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, including BYDUREON [see ADVERSE REACTIONS]. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see ADVERSE REACTIONS]. Monitor renal function in patients reporting adverse reactions to BYDUREON that could lead to volume depletion, especially when initiating BYDUREON.
BYDUREON is not recommended for use in patients with an eGFR below 45 mL/min/1.73 m² [see Use In Specific Populations].
Use of GLP-1 receptor agonists, including BYDUREON, has been associated with gastrointestinal adverse reactions, sometimes severe [see ADVERSE REACTIONS]. BYDUREON is not recommended in patients with severe gastroparesis.
In the 24- to 30-week treatment periods in Trials 1, 2, 3, 4 and 9 in adult patients with type 2 diabetes mellitus [see Clinical Studies and ADVERSE REACTIONS], BYDUREON-treated patients who had high titer anti-exenatide antibodies (defined as ≥625) had a lower glycemic response compared to BYDUREON-treated patients who did not have anti-exenatide antibodies [see CLINICAL PHARMACOLOGY].
In the 24-week treatment period in Trial 8 in pediatric patients with type 2 diabetes mellitus [see BYDUREON-treated patients who had high titer anti-exenatide antibodies (≥625) appeared to have had a lower glycemic response compared to BYDUREON-treated patients who did not have anti-exenatide antibodies. At Week 24, the mean change in HbAClinical Studies (14.5)]1c from baseline in BYDUREON-treated patients was greater (-0.73%) in those with low titer anti-exenatide antibodies (<625) compared to +0.07% in those with high titer anti-exenatide antibodies [see CLINICAL PHARMACOLOGY].
If there is worsening glycemic control or failure to achieve targeted glycemic control, consider stopping BYDUREON and using alternative antidiabetic therapy.
There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) in patients treated with exenatide. If a hypersensitivity reaction occurs, the patient should discontinue BYDUREON and promptly seek medical advice [see CONTRAINDICATIONS and ADVERSE REACTIONS]. Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYDUREON.
Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported in the postmarketing setting with exenatide use. Drug-induced thrombocytopenia is an immune-mediated reaction, with exenatide-dependent anti-platelet antibodies. In the presence of exenatide, these antibodies cause platelet destruction. If drug-induced thrombocytopenia is suspected, discontinue BYDUREON immediately and do not re-expose the patient to exenatide. Upon discontinuation, thrombocytopenia can persist due to the prolonged exenatide exposure from BYDUREON (about 10 weeks) [see ADVERSE REACTIONS].
There have been postmarketing reports of serious injection-site reactions (e.g., abscess, cellulitis, and necrosis), with or without subcutaneous nodules, with the use of BYDUREON. Isolated cases required surgical intervention [see ADVERSE REACTIONS].
Acute events of gallbladder disease, such as cholelithiasis or cholecystitis, have been reported in GLP-1 receptor agonist trials and postmarketing. In the EXSCEL trial [see Clinical Studies], 1.9% of BYDUREON-treated patients and 1.4% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
BYDUREON delays gastric emptying [see CLINICAL PHARMACOLOGY]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking BYDUREON, including whether modifying preoperative fasting recommendations or temporarily discontinuing BYDUREON could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking BYDUREON.
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Inform patients that exenatide extended-release causes benign and malignant thyroid C-cell tumors in rats and that the human relevance of this finding has not been determined. Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea) to their physician [see BOXED WARNING and WARNINGS AND PRECAUTIONS].
Inform patients of the potential risk for acute pancreatitis and its symptoms: severe abdominal pain that may radiate to the back, and which may or may not be accompanied by vomiting. Instruct patients to discontinue BYDUREON promptly and contact their physician if pancreatitis is suspected [see WARNINGS AND PRECAUTIONS].
Inform patients that the risk of hypoglycemia is increased when BYDUREON is used in combination with an agent that induces hypoglycemia, such as a sulfonylurea or insulin. Educate patients on the signs and symptoms of hypoglycemia [see WARNINGS AND PRECAUTIONS].
Inform patients of the potential risk of acute kidney injury due to dehydration associated with gastrointestinal adverse reactions. Advise patients to take precautions to avoid fluid depletion. Inform patients of the signs and symptoms of acute kidney injury and instruct them to promptly report any of these signs or symptoms or persistent (or extended) nausea, vomiting, and diarrhea to their healthcare provider. [see WARNINGS AND PRECAUTIONS].
Inform patients of the potential risk of severe gastrointestinal adverse reactions. Instruct patients to contact their healthcare provider if they have severe or persistent gastrointestinal symptoms [see WARNINGS AND PRECAUTIONS].
Inform patients that serious hypersensitivity reactions have been reported during postmarketing use of exenatide. Inform patients that if symptoms of hypersensitivity reactions occur, stop taking BYDUREON and seek medical advice promptly [see WARNINGS AND PRECAUTIONS].
Inform patients that drug-induced immune-mediated thrombocytopenia has been reported during use of exenatide. Inform patients that if symptoms of thrombocytopenia occur, e.g. bleeding, stop taking BYDUREON and seek medical advice promptly [see WARNINGS AND PRECAUTIONS].
Inform patients that there have been postmarketing reports of serious injection-site reactions with or without subcutaneous nodules, with the use of BYDUREON. Isolated cases of injection-site reactions required surgical intervention. Advise patients to seek medical advice if symptomatic nodules occur, or for any signs or symptoms of abscess, cellulitis, or necrosis [see WARNINGS AND PRECAUTIONS].
Inform patients of the potential risk for cholelithiasis or cholecystitis. Instruct patients to contact their physician if cholelithiasis or cholecystitis is suspected for appropriate clinical follow-up [see WARNINGS AND PRECAUTIONS].
Inform patients that BYDUREON may cause their stomach to empty more slowly which may lead to complications with anesthesia or deep sedation during planned surgeries or procedures. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking BYDUREON [see WARNINGS AND PRECAUTIONS].
Train patients on how to use BYDUREON properly prior to administration. Instruct patients and caregivers on proper mixing and injection technique to ensure the product is adequately mixed and a full dose is delivered. Instruct caregivers to assist pediatric patients with mixing and administration. Refer patients and caregivers to the accompanying Instructions for Use for complete administration instructions with illustrations [see DOSAGE AND ADMINISTRATION].
If a patient is currently taking BYETTA, it should be discontinued upon starting BYDUREON. Inform patients formerly on BYETTA who start BYDUREON that they may experience transient elevations in blood glucose concentrations, which generally improve within the first 2 weeks after initiation of therapy [see DOSAGE AND ADMINISTRATION and Clinical Studies].
Thyroid C-cell tumors have been observed in rats and mice with GLP-1 receptor agonists.
A 2-year carcinogenicity study was conducted with exenatide extended-release, the active component of BYDUREON, in male and female rats at doses of 0.3, 1.0, and 3.0 mg/kg (2-, 9-, and 26-times human systemic exposure at the maximum recommended human dose (MRHD) of 2 mg/week BYDUREON based on plasma exenatide AUC, respectively) administered by subcutaneous injection every other week. In this study there was an increased incidence of C-cell adenomas and C-cell carcinomas at all doses. An increase in benign fibromas was seen in the skin subcutis at injection sites of males given 3 mg/kg. No treatment-related injection-site fibrosarcomas were observed at any dose. The human relevance of these findings is currently unknown.
Carcinogenicity of exenatide extended-release has not been evaluated in mice.
Exenatide, the active ingredient in BYDUREON, was not mutagenic or clastogenic, with or without metabolic activation, in the Ames bacterial mutagenicity assay or chromosomal aberration assay in Chinese hamster ovary cells. Exenatide was negative in the in vivo mouse micronucleus assay.
In mouse fertility studies with exenatide, the active ingredient in BYDUREON, at twice-daily subcutaneous doses of 6, 68, or 760 mcg/kg/day, males were treated for 4 weeks prior to and throughout mating, and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 760 mcg/kg/day, a systemic exposure 148 times the human exposure resulting from the recommended dose of 2 mg/week, based on AUC.
Limited data with exenatide, the active ingredient in BYDUREON, in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). Based on animal reproduction studies, there may be risks to the fetus from exposure to BYDUREON during pregnancy. BYDUREON should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Animal reproduction studies identified increased adverse fetal and neonatal outcomes from exposure to exenatide extended-release during pregnancy, or from exposure to exenatide, during pregnancy and lactation, in association with maternal effects. In rats, exenatide extended-release administered during the period of organogenesis reduced fetal growth and produced skeletal ossification deficits at doses that approximate clinical exposures at the maximum recommended human dose (MRHD) of 2 mg/week. In mice, exenatide administered during gestation and lactation caused increased neonatal deaths at doses that approximate clinical exposures at the MRHD (see Data). Based on animal data, advise pregnant women of the potential risk to a fetus.
The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with an HbA1c >7 and has been reported to be as high as 20-25% in women with HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Disease-Associated Maternal And/Or Embryofetal Risk
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.
Animal Data
Pregnant rats given subcutaneous doses of 0.3, 1, or 3 mg/kg exenatide extended-release every 3 days during organogenesis had systemic exposures 3-, 7-, and 17-times human exposure, respectively, at the maximum recommended human dose (MRHD) of 2 mg/week BYDUREON based on plasma exenatide exposure (AUC) comparison. Reduced fetal growth at all doses and skeletal ossification deficits at 1 and 3 mg/kg occurred at doses that decreased maternal food intake and body weight gain.
In studies evaluating reproduction and development in pregnant mice and rabbits, maternal animals were administered exenatide, the active ingredient in BYDUREON, by subcutaneous injection twice a day. Differences in embryo-fetal developmental toxicity from subcutaneously injected exenatide extended-release and exenatide were not evaluated in mice, rats, or rabbits.
In pregnant mice given 6, 68, 460, or 760 mcg/kg/day exenatide during fetal organogenesis, skeletal variations associated with slowed fetal growth, including changes in number of rib pairs or vertebral ossifications sites, and wavy ribs were observed at 760 mcg/kg/day, a dose that produced maternal toxicity and yielded systemic exposure 200 times the human exposure resulting from the MRHD of BYDUREON based on AUC comparison.
In pregnant rabbits given 0.2, 2, 22, 156, or 260 mcg/kg/day exenatide during fetal organogenesis, irregular fetal skeletal ossifications were observed at 2 mcg/kg/day, a dose yielding systemic exposure up to 4 times the human exposure from the MRHD of BYDUREON based on AUC comparison.
In maternal mice given 6, 68, or 760 mcg/kg/day exenatide from gestation day 6 through lactation day 20 (weaning), an increased number of neonatal deaths were observed on postpartum days 2 to 4 in dams given 6 mcg/kg/day, a dose yielding a systemic exposure equivalent to the human exposure from the MRHD of BYDUREON based on AUC comparison.
There is no information regarding the presence of exenatide in human milk, the effects of exenatide on the breastfed infant, or the effects of exenatide on milk production. Exenatide, the active ingredient in BYDUREON, was present in the milk of lactating mice. However, due to species-specific differences in lactation physiology, the clinical relevance of these data is not clear (see Data).
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for exenatide and any potential adverse effects on the breastfed child from exenatide or from the underlying maternal condition.
In lactating mice subcutaneously injected twice a day with exenatide, the active ingredient in BYDUREON, the concentration of exenatide in milk was up to 2.5% of the concentration in maternal plasma.
Pediatric Use
The safety and effectiveness of BYDUREON as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients aged 10 years and older. Use of BYDUREON for this indication is supported by a 24-week placebo-controlled trial with 28-week open-label uncontrolled extension (Trial 8) in 82 pediatric patients 10 years of age and older with type 2 diabetes, a pediatric pharmacokinetic study, and studies in adults with type 2 diabetes mellitus [see CLINICAL PHARMACOLOGY and Clinical Studies].
The safety and effectiveness of BYDUREON have not been established in pediatric patients less than 10 years of age.
In five comparator-controlled 24- to 30-week trials, BYDUREON was studied in 132 patients (17%) who were between 65 years of age and 75 years of age and 20 (2.5%) patients who were at least 75 years of age. In these studies, no meaningful differences in safety (N=152) and effectiveness (N=52) were observed between patients ≥65 years of age and younger adult patients, but these studies did not include sufficient numbers of patients ≥75 years of age to determine whether they respond differently from younger adult patients.
In a large cardiovascular outcomes trial [see Clinical Studies], BYDUREON was studied in 2,959 patients (40%) who were at least 65 years old and of those, 605 patients (8%) were at least 75 years old.
Use caution when initiating BYDUREON in geriatric patients because they are more likely to have decreased kidney function [see Use In Specific Populations].
Pharmacokinetic studies of adult patients with renal impairment who received BYDUREON indicate that there is an increase in exenatide exposure in those with mild and moderate renal impairment as compared to patients with normal kidney function. BYDUREON may induce nausea and vomiting with transient hypovolemia and may worsen kidney function in patients with renal impairment.
Monitor patients with mild renal impairment for adverse reactions that may lead to hypovolemia. BYDUREON is not recommended for use in patients with eGFR below 45 mL/min/1.73 m² or end stage renal disease. If BYDUREON is used in patients with renal transplantation, closely monitor for adverse reactions that may lead to hypovolemia [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].
Effects of overdoses with BYETTA, another exenatide product, included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations, including severe hypoglycemia requiring parenteral glucose administration. In the event of overdose, consider contacting the Poison Help line (1-800-222Â1222) or a medical toxicologist for additional overdosage management recommendations. Initiate appropriate supportive treatment according to the patient's clinical signs and symptoms.
BYDUREON is contraindicated in patients with a:
Incretins, such as GLP-1, enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYDUREON is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.
The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide is a GLP-1 receptor agonist that has been shown to bind and activate the human GLP-1 receptor in vitro. This leads to an increase in both glucose-dependent synthesis of insulin and in vivo secretion of insulin from pancreatic beta cells, by mechanisms involving cyclic AMP and/or other intracellular signaling pathways. Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations.
Exenatide improves glycemic control through the actions described below.
The effect of exenatide infusion on glucose-dependent insulin secretion rates (ISR) was investigated in 11 healthy subjects. In these healthy subjects, on average, the ISR response was glucose-dependent (Figure 1). Exenatide did not impair the normal glucagon response to hypoglycemia.
Figure 1: Mean (SE) Insulin Secretion Rates During Infusion of Exenatide or Placebo by Treatment, Time, and Glycemic Condition in Healthy Subjects
 |
SE = standard error.
Notes: 5 mmol = 90 mg/dL, 4 mmol/L = 72 mg/dL, 3.2 mmol/L = 58 mg/dL; Study medication infusion was started at time = 0 minutes.
Statistical assessments were for the last 30 minutes of each glycemic step, during which the target glucose concentrations were maintained.
*p <0.05, exenatide treatment relative to placebo.
In patients with type 2 diabetes, exenatide moderates glucagon secretion and lowers serum glucagon concentrations during periods of hyperglycemia.
Exenatide slows gastric emptying, thereby reducing the rate at which postprandial glucose appears in the circulation.
In a clinical study in adults with type 2 diabetes mellitus, treatment with once weekly BYDUREON resulted in mean reductions in fasting plasma glucose of -45 mg/dL and 2-hour PPG concentrations of -95 mg/dL.
The effect of exenatide at therapeutic (253 pg/mL) and supratherapeutic (627 pg/mL) concentrations, following an intravenous infusion on QTc interval was evaluated in a randomized, placebo- and active-controlled (moxifloxacin 400 mg) three-period crossover thorough QT study in 74 healthy subjects. The upper bound of the one-sided 95% confidence interval for the largest placebo adjusted, baseline-corrected QTc based on population correction method (QTcP) was below 10 ms. Therefore, exenatide was not associated with prolongation of the QTc interval at therapeutic and supratherapeutic concentrations.
Following a single dose of BYDUREON, exenatide is released from the microspheres over approximately 10 weeks. There is an initial period of release of surface-bound exenatide followed by a gradual release of exenatide from the microspheres, which results in two subsequent peaks of exenatide in plasma at around Week 2 and Week 6 to 7, respectively, representing the hydration and erosion of the microspheres.
Following initiation of once every 7 days (weekly) administration of 2 mg BYDUREON, a gradual increase in the plasma exenatide concentration is observed over 6 to 7 weeks. After 6 to 7 weeks, mean exenatide concentrations of approximately 300 pg/mL were maintained over once every 7 days (weekly) dosing intervals indicating that steady state was achieved.
The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of BYETTA is 28.3 L and is expected to remain unchanged for BYDUREON.
Elimination
Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. The mean apparent clearance of exenatide in humans is 9.1 L/hour and is independent of the dose. Approximately 10 weeks after discontinuation of BYDUREON therapy, plasma exenatide concentrations generally fall below the minimal detectable concentration of 10 pg/mL.
BYDUREON has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease receiving dialysis. Population pharmacokinetic analysis of renally impaired patients receiving 2 mg BYDUREON indicate that there is a 62% and 33% increase in exposure in moderate (N=10) and mild (N=56) renally impaired patients, respectively, as compared to patients with normal renal function (N=84).
In a study of BYETTA in subjects with end-stage renal disease receiving dialysis, mean exenatide exposure increased by 3.4-fold compared to that of subjects with normal renal function [see Use In Specific Populations].
BYDUREON has not been studied in patients with acute or chronic hepatic impairment.
Age, gender, race and body weight did not alter the pharmacokinetics of BYDUREON in population pharmacokinetic analyses.
The clinical pharmacology of BYDUREON has been evaluated in the population pharmacokinetic study in adolescent patients with type 2 diabetes mellitus between age 11 and age less than 18 years old. The pharmacokinetic profile of BYDUREON in the pediatric population was consistent with that of the adults.
When 1000 mg acetaminophen tablets were administered, either with or without a meal, following 14 weeks of BYDUREON therapy (2 mg weekly), no significant changes in acetaminophen AUC were observed compared to the control period. Acetaminophen Cmax decreased by 16% (fasting) and 5% (fed) and Tmax was increased from approximately 1 hour in the control period to 1.4 hours (fasting) and 1.3 hours (fed).
The following drug interactions have been studied using BYETTA. The potential for drug-drug interaction with BYDUREON is expected to be similar to that of BYETTA.
Administration of warfarin (25 mg) 35 minutes after repeated doses of BYETTA (5 mcg twice daily on days 1-2 and 10 mcg twice daily on days 3-9) in healthy volunteers delayed warfarin Tmax by approximately 2 hours. No clinically relevant effects on Cmax or AUC of S-and R-enantiomers of warfarin were observed. BYETTA did not significantly alter the pharmacodynamic properties (e.g., international normalized ratio) of warfarin [see DRUG INTERACTIONS].
Administration of repeated doses of BYETTA 30 minutes before oral digoxin (0.25 mg once daily) decreased the Cmax of digoxin by 17% and delayed the Tmax of digoxin by approximately 2.5 hours; however, the overall steady-state pharmacokinetic exposure (e.g., AUC) of digoxin was not changed.
Administration of BYETTA (10 mcg twice daily) 30 minutes before a single oral dose of lovastatin (40 mg) decreased the AUC and Cmax of lovastatin by approximately 40% and 28%, respectively, and delayed the Tmax by about 4 hours compared with lovastatin administered alone. In the 30-week controlled clinical trials of BYETTA, the use of BYETTA in patients already receiving HMG CoA reductase inhibitors was not associated with consistent changes in lipid profiles compared to baseline.
In patients with mild to moderate hypertension stabilized on lisinopril (5-20 mg/day), BYETTA (10 mcg twice daily) did not alter steady-state Cmax or AUC of lisinopril. Lisinopril steady-state Tmax was delayed by 2 hours. There were no changes in 24-hour mean systolic and diastolic blood pressure.
The effect of BYETTA (10 mcg twice daily) on single and on multiple doses of a combination oral contraceptive (30 mcg ethinyl estradiol plus 150 mcg levonorgestrel) was studied in healthy female subjects. Repeated daily doses of the oral contraceptive (OC) given 30 minutes after BYETTA administration decreased the Cmax of ethinyl estradiol and levonorgestrel by 45% and 27%, respectively, and delayed the Tmax of ethinyl estradiol and levonorgestrel by 3.0 hours and 3.5 hours, respectively, as compared to the oral contraceptive administered alone. Administration of repeated daily doses of the OC one hour prior to BYETTA administration decreased the mean Cmax of ethinyl estradiol by 15%, but the mean Cmax of levonorgestrel was not significantly changed as compared to when the OC was given alone. BYETTA did not alter the mean trough concentrations of levonorgestrel after repeated daily dosing of the oral contraceptive for both regimens. However, the mean trough concentration of ethinyl estradiol was increased by 20% when the OC was administered 30 minutes after BYETTA administration injection as compared to when the OC was given alone. The effect of BYETTA on OC pharmacokinetics is confounded by the possible food effect on OC in this study [see DRUG INTERACTIONS].
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of BYDUREON or of other exenatide products.
Anti-exenatide antibodies were measured at prespecified intervals (4-14 weeks) in BYDUREON-treated
adult patients (N=918) in five active-controlled trials for the improvement of glycemic control in adults
with type 2 diabetes mellitus (Trials 1, 2, 3, 4 and 9) [see Clinical Studies and ADVERSE REACTIONS]Â. In these five trials, 107/918 (12%) of BYDUREON-treated patients had high titer anti -exenatide antibodies (high titer was defined as ≥625) at endpoint. These patients had a lower glycemic response compared to BYDUREON-treated patients who did not have anti-exenatide antibodies at endpoint [see WARNINGS AND PRECAUTIONS].
In a 30-week, randomized, open-label, controlled trial in adults with type 2 diabetes mellitus [see ADVERSE REACTIONS], anti-exenatide antibody assessments were performed at baseline and at 4-week intervals from Week 6 to Week 30. The mean anti-exenatide antibody titer in the BYDUREON-treated patients peaked at Week 6.
Injection site reactions for BYDUREON-treated patients were more commonly observed in those who were antibody-positive (anti-exenatide antibodies) compared with those who were antibody-negative, with a greater incidence in those with higher titer anti-exenatide antibodies (defined as ≥625) [see ADVERSE REACTIONS]. There is insufficient data to assess whether the observed anti-exenatide antibodies in adults had an effect on the severity of injection site reactions, or on the incidence or severity of hypersensitivity reactions.
A total of 32 adult patients with anti-exenatide antibodies in BYDUREON Trial 9 were tested for the presence of cross-reactive antibodies to GLP-1 and/or glucagon and no treatment-emergent cross-reactive antibodies were observed.
In a 52-week trial (24-week controlled and 28-week extended treatment period) for the improvement of glycemic control in pediatric patients with type 2 diabetes mellitus (Trial 8) [see Clinical Studies], 37/58 (64%) of BYDUREON-treated patients had high titer anti-exenatide antibodies (high titer was defined as ≥625) at any time during the study. In this trial, 60% of these patients had a peak high-titers at approximately Week 12. BYDUREON-treated pediatric patients that had high titer anti-exenatide antibodies appeared to have had a lower glycemic response compared to BYDUREON-treated pediatric patients who did not have anti-exenatide antibodies during this trial [see WARNINGS AND PRECAUTIONS].
There is insufficient data to assess whether the observed anti-exenatide antibodies in pediatric patients had an effect on the incidence or severity of hypersensitivity reactions or injection site reactions.
The potential for development of antibodies cross-reactive with endogenous GLP-1 and glucagon has not been evaluated in BYDUREON-treated pediatric patients.
The percentage of exenatide-treated adult and pediatric patients (age ≥11 years) with high anti-exenatide antibody titers (≥625) that had steady state exenatide plasma concentrations below limit of quantitation was higher than in those with low anti-exenatide antibody titers (<625).
BYDUREON has been studied in adult patients with type 2 diabetes mellitus as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, a combination of metformin and a thiazolidinedione, in combination with a sodium-glucose cotransporter-2 (SGLT2) inhibitor on a background of metformin, and in combination with basal insulin [see Clinical Studies].
Cardiovascular (CV) outcomes were studied in the EXSCEL trial that enrolled adult patients with type 2 diabetes mellitus and multiple risk factors for CV disease or established CV disease [see Clinical Studies].
BYDUREON has been studied in pediatric patients aged 10 years and older with type 2 diabetes mellitus as monotherapy and in combination with metformin, a sulfonylurea, and in combination with basal insulin with or without metformin [see Clinical Studies].
A 26-week, randomized, comparator-controlled trial was conducted to compare the safety and efficacy of BYDUREON to metformin, sitagliptin, and pioglitazone in adult patients with type 2 diabetes whose glycemic control was inadequate with diet and exercise (Trial 1 -NCT00676338). Patients were randomly assigned to receive BYDUREON 2 mg given subcutaneously once every seven days (weekly), titrated metformin from 1000 to 2500 mg/day, sitagliptin 100 mg/day or titrated pioglitazone from 30 to 45 mg/day, all dosed according to approved labeling.
A total of 820 patients were studied: 552 (67%) were White, 102 (12%) were East Asian, 71 (9%) were West Asian, 65 (8%) were Hispanic or Latino, 25 (3.0%) were Black of African American, 4 (0.5%) were of Native American ethnicity, and 1 was classified otherwise. The mean baseline HbA1c was 8.5%.
The primary endpoint was change in HbA1c from baseline to Week 26 (or the last value at time of early discontinuation).
Efficacy Results
Treatment with BYDUREON 2 mg once weekly (QW) resulted in mean HbA1c reduction that was statistically significantly greater compared to sitagliptin 100 mg/day. The mean reduction in HbA1c was non-inferior compared with metformin 1000-2500 mg/day (mean dose 2077 mg/day at study endpoint). Non-inferiority of BYDUREON 2 mg QW to pioglitazone 30-45 mg/day (mean dose 40 mg/day at study endpoint) in reducing HbA1c after 26 weeks of treatment was not demonstrated (the mean change from baseline in HbA1c after 26 weeks was -1.6% with BYDUREON and -1.7% with pioglitazone). The non-inferiority margin was set at +0.3% in this study. The results for the primary endpoint at 26 weeks are summarized in Table 5.
The proportion of patients with a Week 26 value achieving HbA1c of less than 7% at Week 26 were 56%, 52%, 40%, and 55% for BYDUREON, metformin, sitagliptin, and pioglitazone, respectively. Patients who did achieve HbA1c goal <7% and discontinued before Week 26 were not included as responders. The mean changes from baseline to Week 26 for fasting serum glucose were -41 mg/dL, -36 mg/dL, -20 mg/dL, and -46 mg/dL, and for body weight were -2.0 kg, -2.0 kg, -0.8 kg, and +1.5 kg for BYDUREON, metformin, sitagliptin, and pioglitazone, respectively.
Table 5: Results of 26-Week Trial of BYDUREON Monotherapy versus Metformin, Sitagliptin, and Pioglitazone in Patients with Type 2 Diabetes Mellitus (Trial 1)
| BYDUREON 2 mg QW | Metformin 1000-2500 (mean dose 2077) mg/day | Sitagliptin 100 mg/day | Pioglitazone 30-45 (mean dose 40) mg/day | |
| Intent-to-Treat Population (N) | 248 | 246 | 163 | 163 |
| HbA1c (%) | ||||
| Mean Baseline | 8.4 | 8.6 | 8.4 | 8.5 |
| Mean Change at Week 26* | -1.6 | -1.5 | -1.2 | -1.7 |
| Difference from metformin* [Bonferroni-adjusted 98.3% CI| | -0.05 [-0.26, 0.171 |
|||
| Difference from sitagliptin* [Bonferroni-adjusted 98.3% CI| | -0.39† [-0.63, -0.161 |
|||
| Difference from pioglitazone* [Bonferroni-adjusted 98.3% CI| | 0.16 [-0.08, 0.411 |
|||
| N = number of patients in each treatment group; mean change is least squares mean change; QW = once weekly. The primary efficacy analysis was adjusted for multiple comparisons and a two-sided 98.3% confidence interval was utilized to assess difference between treatments. HbA1c change data at 26 weeks were available from 86%, 87%, 85%, and 82% of the randomized subjects in the BYDUREON, metformin, sitagliptin, and pioglitazone groups, respectively. * Least squares means were obtained using a mixed model repeated measure analysis with treatment, pooled country, visit, baseline HbA1c value, and treatment by visit interaction as fixed effects, and subject as a random effect. † p<0.001, treatment vs comparator. |
||||
A 26-week double-blind comparator-controlled trial was conducted to compare the safety and efficacy of BYDUREON to sitagliptin and pioglitazone in patients with type 2 diabetes whose glycemic control was inadequate with metformin therapy (Trial 2 -NCT00637273). Patients were randomly assigned to receive BYDUREON 2 mg given subcutaneously once every 7 days (weekly), sitagliptin 100 mg/day or pioglitazone 45 mg/day, in addition to their existing metformin therapy.
A total of 491 patients were studied 168 (34.2%) were White, 143 (29.1%) were Hispanic or Latino, 119 (24.2%) were Asian, 52 (10.6%) were Black or African American, 3 (0.6%) were of Native American ethnicity, and 6 (1.2%) were classified otherwise. The mean baseline HbA1c was 8.5%.
The primary endpoint was change in HbA1c from baseline to Week 26 (or the last value at time of early discontinuation).
Efficacy Results
In this study, treatment with BYDUREON 2 mg QW resulted in a statistically significant mean HbA1c reduction compared to sitagliptin 100 mg/day. There was a numerically greater reduction in HbA1c with BYDUREON compared to pioglitazone, but there was not sufficient evidence to conclude superiority of BYDUREON 2 mg QW to pioglitazone 45 mg/day in reducing HbA1c after 26 weeks of treatment. Results for the primary endpoint at 26 weeks are summarized in Table 6.
The proportion of patients with a Week 26 value achieving HbA1c of less than 7% at Week 26 were 46%, 30%, and 39% for BYDUREON, sitagliptin, and pioglitazone, respectively. Patients who did achieve an HbA1c goal <7% and discontinued before Week 26 were not included as responders. The mean changes from baseline to Week 26 for fasting serum glucose were -32 mg/dL, -16 mg/dL and -27 mg/dL, and for body weight were -2.3 kg, -0.8 kg and +2.8 kg for BYDUREON, sitagliptin, and pioglitazone, respectively.
Table 6: Results of 26-Week Trial of BYDUREON versus Sitagliptin and Pioglitazone, All as Add-On to Metformin Therapy in Patients with Type 2 Diabetes Mellitus (Trial 2)
| BYDUREON 2 mg QW | Sitagliptin 100 mg/day | Pioglitazone 45 mg/day | |
| Intent-to-Treat Population (N) | 160 | 166 | 165 |
| HbA1c (%) | |||
| Mean Baseline | 8.6 | 8.5 | 8.5 |
| Mean Change at Week 26* | -1.5 | -0.9 | -1.2 |
| Difference from sitagliptin* [95% CI] | -0.63 [-0.89, -0.37] |
||
| Difference from pioglitazone* [95% CI] | -0.32 [-0.57, -0.06] |
||
| N = number of patients in each treatment group; mean change is least squares mean change; QW = once weekly. * Least squares means were obtained using an ANCOVA model with treatment, baseline HbA1c stratum, and country as fixed effects. Missing Week 26 data (28%, 18%, and 24% for the BYDUREON, sitagliptin, and pioglitazone groups, respectively) were imputed by the LOCF technique. |
|||
A 26-week open-label comparator-controlled trial was conducted to compare the safety and efficacy of BYDUREON to titrated insulin glargine in patients with type 2 diabetes whose glycemic control was inadequate with metformin or metformin plus sulfonylurea therapy (Trial 3 -NCT00641056). Patients were randomly assigned to receive BYDUREON 2 mg given subcutaneously once every 7 days (weekly) or insulin glargine once daily in addition to their existing oral antidiabetic therapy. Insulin glargine was dosed to a target fasting glucose concentration of 72 to 100 mg/dL.
The mean dose of insulin glargine was 10 units/day at baseline and 31 units/day at endpoint. At Week 26, 21% of insulin glargine treated patients were at fasting glucose goal.
A total of 456 patients were studied: 379 (83.1%) were White, 47 (10.3%) were Hispanic or Latino 25 (5.5%) were East Asian, 3 (0.7%) were Black or African American, and 2 (0.4%) were of West Asian ethnicity. Background therapy was either metformin (70%) or metformin plus sulfonylurea (30%). The mean baseline HbA1c was 8.3%.
The primary endpoint was change in HbA1c from baseline to Week 26 (or the last value at time of early discontinuation).
Efficacy Results
Treatment with BYDUREON once weekly resulted in a mean reduction in HbA1c from baseline at 26 weeks of -1.5%. The mean reduction in HbA1c seen in insulin glargine arm at 26 weeks was -1.3%. The difference in observed effect size between BYDUREON and glargine in this trial excluded the preÂspecified non-inferiority margin of +0.3%.
The proportion of patients with a Week 26 value achieving HbA1c of less than 7% at Week 26 were 57% and 48% for BYDUREON and insulin glargine, respectively. Patients who did achieve an HbA1c goal <7% and discontinued before Week 26 were not included as responders. The mean changes from baseline to Week 26 for fasting serum glucose in this study were -38 mg/dL and -50 mg/dL, and for body weight were -2.6 kg and +1.4 kg for BYDUREON and insulin glargine, respectively.
A 24-week, randomized, open-label trial was conducted to compare the safety and efficacy of BYDUREON to BYETTA in patients with type 2 diabetes and inadequate glycemic control with diet and exercise alone or with oral antidiabetic therapy, including metformin, a sulfonylurea, a thiazolidinedione, or combination of two of those therapies (Trial 4 -NCT00877890). Patients were randomly assigned to receive BYDUREON 2 mg subcutaneously once every 7 days (weekly) or BYETTA (10 mcg subcutaneously twice daily), in addition to existing oral antidiabetic agents. Patients assigned to BYETTA initiated treatment with 5 mcg twice daily then increased the dose to 10 mcg twice daily after 4 weeks.
A total of 252 patients were studied: 149 (59%) were White, 78 (31%) were Hispanic or Latino, 15 (6%) were Black or African American, and 10 (4%) were of Asian ethnicity. Patients were treated with diet and exercise alone (19%), a single oral antidiabetic agent (47%), or combination therapy of oral antidiabetic agents (35%). The mean baseline HbA1c was 8.4%.
The primary endpoint was change in HbA1c from baseline to Week 24 (or the last value at time of early discontinuation).
Efficacy Results
Treatment with BYDUREON 2 mg QW resulted in a statistically significantly greater mean HbA1c reduction compared to BYETTA 10 mcg twice daily. Change in body weight was a secondary endpoint. Twenty-four-week study results are summarized in Table 7.
Reductions from mean baseline (97/94 kg) in body weight were observed in both BYDUREON (-2.3 kg) and BYETTA (-1.4 kg) treatment groups.
Table 7: Results of 24-Week Trial of BYDUREON versus BYETTA, Both as Monotherapy or as Add-On to Metformin, a Sulfonylurea, a Thiazolidinedione, or Combination of Oral Agents in Patients with Type 2 Diabetes Mellitus (Trial 4)
| BYDUREON 2 mg QW | BYETTA 10 mcg twice daily* | |
| Intent-to-Treat Population (N) | 129 | 123 |
| HbA1c (%) | ||
| Mean Baseline | 8.5 | 8.4 |
| Mean Change at Week 24† | -1.6 | -0.9 |
| Difference from BYETTA† [95% CI] | −0.7 [−0.9, −0.4]‡ |
|
| Percentage Achieving HbA1c <7% at Week 24 (%) | 58‡ | 30 |
| Fasting Plasma Glucose (mg/dL) | ||
| Mean Baseline | 173 | 168 |
| Mean Change at Week 24 | -25 | -5 |
| Difference from BYETTA† [95% CI] | −20 [−31, −10]‡ |
|
| N = number of patients in each treatment group; mean change is least squares mean change; QW = once weekly. * BYETTA 5 mcg twice daily before the morning and evening meals for 4 weeks followed by 10 mcg twice daily for 20 weeks. † Least squares (LS) means are adjusted for baseline HbA1c strata, background antihyperglycemic therapy, and baseline value of the dependent variable (if applicable). ‡ p<0.001, treatment vs comparator. |
||
A 26-week open-label comparator-controlled trial was conducted to compare the safety and efficacy of BYDUREON to liraglutide in patients with type 2 diabetes whose glycemic control was inadequate with metformin, a sulfonylurea, metformin plus sulfonylurea, or metformin plus pioglitazone therapy (Trial 5 -NCT01029886). Patients were randomly assigned to receive BYDUREON 2 mg given subcutaneously once every 7 days (weekly) or liraglutide uptitrated from 0.6 mg/day to 1.2 mg/day, then 1.8 mg/day in addition to their existing oral antidiabetic therapy. Each titration was to be completed after at least one week, but could be delayed if the patient had severe nausea or vomiting as established by the investigator. Patients not tolerating the 1.8 mg/day dose of liraglutide by Week 4 were discontinued from the study.
A total of 911 patients were studied: 753 (82.7%) were White, 111 (12.2%) were Asian, 32 (3.5%) were American Indian or Alaska Native, 8 (0.9%) were of Black or African American ethnicity, 6 (0.7%) were multiple races, and 1 (0.1%) was Pacific Islander. Background therapy was either a single oral antidiabetic agent (35%) or a combination of oral antidiabetic agents (65%). The mean baseline HbA1c was 8.4%.
The primary endpoint was change in HbA1c from baseline to Week 26 (or the last value at time of early discontinuation).
Efficacy Results
Treatment with BYDUREON once weekly resulted in a mean reduction in HbA1c from baseline at 26 weeks of -1.3%. The mean reduction in HbA1c seen in the liraglutide arm at 26 weeks was -1.5%. The HbA1c reduction with BYDUREON did not meet predefined non-inferiority criteria compared to liraglutide 1.8 mg/day. The non-inferiority margin was set at +0.25% in this study. Results for the primary endpoint at 26 weeks are summarized in Table 8.
The proportion of patients with a Week 26 value achieving HbA1c of less than 7% at Week 26 were 48% and 56% for BYDUREON and liraglutide, respectively. Patients who did achieve an HbA1c goal <7% and discontinued before Week 26 were not included as responders. The mean changes from baseline to Week 26 for fasting serum glucose were -32 mg/dL and -38 mg/dL, and for body weight were -2.7 kg and -3.6 kg for BYDUREON and liraglutide, respectively.
Table 8: Results of 26-Week Trial of BYDUREON versus Liraglutide, Both as Add-On to Metformin, a Sulfonylurea, Metformin + Sulfonylurea, or Metformin + Pioglitazone Therapy in Patients with Type 2 Diabetes Mellitus (Trial 5)
| BYDUREON 2 mg QW | Liraglutide 1.8 mg/day | |
| Intent-to-Treat Population (N) | 461 | 450 |
| HbA1c (%) | ||
| Mean Baseline | 8.5 | 8.4 |
| Mean Change at Week 26* | -1.3 | -1.5 |
| Difference from liraglutide* [95% CI] | 0.2 [0.08, 0.331 |
|
| N = number of patients in each treatment group; mean change is least squares mean change; QW = once weekly. HbA1c change data at 26 weeks were available from 85% and 86% of the randomized subjects in the BYDUREON and liraglutide groups, respectively. * Least squares means were obtained using a mixed model repeated measure analysis with treatment, country, OAD stratum, baseline HbA1c stratum, visit, baseline HbA1c, and treatment by visit interaction as fixed effects, and subject as a random effect. |
||
A 28-week double-blind comparator-controlled trial was conducted to compare the efficacy of BYDUREON and dapagliflozin (an SGLT2 inhibitor) to BYDUREON alone and dapagliflozin alone in patients with type 2 diabetes with inadequate glycemic control with metformin therapy (Trial 6 -NCT02229396). All patients entered a 1-week placebo lead–in period. Patients with HbA1c ≥8.0% and ≤12% and on metformin at a dose of at least 1,500 mg per day were randomly assigned to receive either BYDUREON 2 mg given subcutaneously once every 7 days (weekly) plus dapagliflozin 10 mg once daily, BYDUREON 2 mg given subcutaneously once weekly, or dapagliflozin 10 mg once daily.
A total of 694 patients were studied; 580 (83.6%) were White, 96 (13.8%) were Black or African American, 5 (0.7%) were of Asian ethnicity, 2 (0.3%) were American Indian or Alaska Native and 11 (1.6%) were classified otherwise. The mean baseline HbA1c was 9.3%.
The primary endpoint was change in HbA1c from baseline to Week 28.
Efficacy Results
At Week 28, BYDUREON in combination with dapagliflozin provided statistically significantly greater reductions in HbA1c (-1.77%) compared to BYDUREON alone (-1.42%, p=0.012) and dapagliflozin alone (-1.32%, p=0.001). BYDUREON in combination with dapagliflozin provided statistically significantly greater reductions in FPG (-57.35 mg/dL) compared to BYDUREON alone (-40.53, p <0.001) and dapagliflozin alone (-44.72 mg/dL, p=0.006).
A 28-week, double-blind, placebo-controlled trial was conducted to compare the safety and efficacy of BYDUREON to placebo when added to basal insulin glargine, with or without metformin, in patients with type 2 diabetes with inadequate glycemic control (Trial 7 -NCT02229383). Patients on sulfonylurea therapy discontinued sulfonylurea. Patients on metformin continued on the same dose of metformin. All patients initially entered an 8-week insulin dose-titration phase. Insulin glargine was to be titrated every 3 days with an aim of achieving a target fasting plasma glucose concentration of 72 to 99 mg/dL. Following the titration period, patients with HbA1c ≥7.0% and ≤10.5% were then randomly assigned to receive either BYDUREON 2 mg given subcutaneously once every 7 days (weekly) or placebo once every 7 days (weekly).
A total of 460 patients were studied: 400 (87.0%) were White, 47 (10.2%) were Black or African American, 6 (1.3%) were of Asian ethnicity, 1 (0.2%) was American Indian or Alaska Native, 1 (0.2%) was Pacific Islander and 5 (1.1%) were classified otherwise.
The primary endpoint was the change in HbA1c from baseline to Week 28.
Efficacy Results
Compared to placebo, treatment with BYDUREON resulted in a statistically significant reduction in mean HbA1c from baseline to Week 28 (Table 9).
The mean change in fasting plasma glucose from baseline to Week 28 was -12.50 mg/dL for BYDUREON and -2.26 mg/dL for placebo. The mean change from baseline to Week 28 in body weight was -0.92 kg for BYDUREON and +0.38 kg for placebo.
Table 9: Results of 28-Week Trial of BYDUREON versus Placebo, Both as Add-On to Insulin Glargine or Insulin Glargine + Metformin (Trial 7)
| BYDUREON 2 mg QW | Placebo QW | |
| Intent-to-Treat Population (N) | 231 | 229 |
| Mean HbA1c (%) | ||
| Mean Baseline | 8.53 | 8.53 |
| Mean Change at Week 28* | -0.88 (0.070) | -0.24 (0.069) |
| Difference from Placebo [95% CI] | -0.641† [-0.83, -0.45] |
|
| Percentage Achieving HbA1c <7.0% at Week 28 (%)‡ | 32.5† | 7.0 |
| N = number of patients in each treatment group, CI=confidence interval, QW=once weekly. Note: mean change is least squares mean change. *Adjusted LS means and treatment group difference(s) in the change from baseline values at Week 28 using a multiple imputation method that models a “wash-out” for patients having missing data who discontinued treatment. ANCOVA was used with treatment, region, baseline HbA1c stratum (<9.0% or ≥9.0%), and baseline SU-use stratum (yes vs. no) as fixed factors, and baseline value as a covariate. † p-value <0.001 (adjusted for multiplicity). ‡ Categories are derived from continuous measurements. All patients with missing endpoint data are imputed as non-responders. Treatment comparison is based on Cochran-Mantel-Haenszel (CMH) test stratified by baseline HbA1c (<9.0% or ≥9.0%), and baseline SU-use stratum (yes vs. no). P-values are from the general association statistics. Analyses include measurements post rescue therapy and post premature discontinuation of study medication. |
||
EXSCEL was a multinational, placebo-controlled, double-blind, randomized, parallel group pragmatic study that evaluated cardiovascular (CV) outcomes during treatment with BYDUREON in adult patients with type 2 diabetes and any level of CV risk when added to the current usual care (NCT01144338). A total of 14,752 adult patients were randomized 1:1 to either BYDUREON 2 mg given subcutaneously once weekly or placebo and followed as in routine clinical practice for a median of 38.7 months with a median treatment duration of 27.8 months.
Ninety six percent of the patients in both treatment groups completed the study in accordance with the protocol, and the vital status was known at the end of the study for 98.9% and 98.8% of the patients in the BYDUREON and placebo group, respectively. The mean age at study entry was 62 years (21 to 92 years with 8.5% of the patients ≥75 years). Approximately 62.0% of the patients were male, 75.8% were White, 9.8% were Asian, 6.0% were Black or African American, and 20.5% were of Hispanic or Latino ethnicity. The mean BMI was 32.7 kg/m² and the mean duration of diabetes was 13.1 years. Approximately 49.3% had mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to ≤89 mL/min/1.73 m²) and 21.6% had moderate renal impairment (eGFR ≥30 to ≤59 mL/min/1.73 m²).
The mean HbA1c was 8.1%. At baseline, 1.5% of patients were not treated with either oral antidiabetic medications or insulin, 42.3% were treated with one oral antidiabetic medication and 42.4% were treated with two or more oral antidiabetic medications. Usage of oral antidiabetic medications included metformin (76.6%), sulfonylurea (36.6%), dipeptidyl peptidase-4 (DPP-4) inhibitors (14.9%), thiazolidinediones (3.9%), and SGLT2 inhibitors (0.9%). Overall insulin usage was 46.3% (13.8% with insulin alone and 32.6% with insulin and one or more oral antidiabetic medications).
Overall, at baseline, 26.9% of patients did not have established cardiovascular (CV) disease, while 73.1% had established CV disease. The concomitant use of CV medications (e.g., ACE inhibitors, angiotensin receptor blockers, diuretics, beta blockers, calcium channel blockers, antithrombotic and anticoagulants, and lipid-lowering agents) was similar in the BYDUREON and placebo groups. At baseline, the mean systolic blood pressure was 135.5 mmHg, the mean diastolic blood pressure was 78.1 mmHg, the mean LDL was 95.0 mg/dL, and the mean HDL was 44.0 mg/dL.
The primary endpoint in EXSCEL was the time to first confirmed Major Adverse Cardiac Event (MACE) from randomization. MACE was defined as occurrence of either a cardiovascular (CV)-related death, or a nonfatal myocardial infarction (MI) or a nonfatal stroke. All-cause mortality, CV-related death, and fatal or nonfatal MI or stroke, hospitalization for acute coronary syndrome, and hospitalization for heart failure were also assessed as secondary endpoints.
A Cox proportional hazards model was used to test for non-inferiority against the pre-specified risk margin of 1.3 for the hazard ratio of MACE and superiority on MACE if non-inferiority was demonstrated. Type-1 error was controlled across multiple tests using a hierarchical testing strategy.
MACE Results
BYDUREON did not increase the risk of MACE in adult patients with type 2 diabetes mellitus (HR: 0.91; 95% CI: 0.832, 1.004; P<0.001 for non-inferiority; P=0.06 for superiority). See results in Table 10 and Figure 2. The incidence of MACE in patients with and without established CV disease was 13.4% in the BYDUREON group versus 14.6% in the placebo group and 6.0% (BYDUREON) versus 5.9% (placebo), respectively. Five hundred and seven (507) patients (6.9%) died in the BYDUREON group versus 584 (7.9%) in the placebo group.
Table 10: Analysis of Primary Composite Endpoint MACE and Its Components in Adult Patients with Type 2 Diabetes (EXSCEL)
| BYDUREON N=7356 |
Placebo N=7396 |
HR* (95% CI) | |
| MACE Composite of CV death, nonfatal MI or nonfatal stroke (time to first confirmed event) | 839 (11.4%) | 905 (12.2%) | 0.91 (0.832, 1.004) |
| Cardiovascular Death | 340 (4.6%) | 383 (5.2%) | 0.88 (0.76, 1.02) |
| Nonfatal Myocardial Infarction | 466 (6.3%) | 480 (6.5%) | 0.96 (0.85, 1.09) |
| Nonfatal Stroke | 169 (2.3%) | 193 (2.6%) | 0.86 (0.70, 1.06) |
| N=number of patients in each treatment group, HR=hazard ratio, CI=confidence interval, CV=cardiovascular, MI=myocardial infarction. * HR (active/placebo) and CI are based on Cox proportional hazards regression model, stratified by established CV disease, with treatment group only as explanatory variable. |
|||
Figure 2: Time to First Adjudicated MACE in Adult Patients with Type 2 Diabetes (EXSCEL)
 |
HR=hazard ratio, CI=confidence interval.
The efficacy and safety of BYDUREON 2 mg given subcutaneously once weekly or placebo was evaluated in a 24-week randomized, double-blind, placebo-controlled, parallel-group study (Trial 8 -NCT01554618) in 82 patients aged 10 to 17 years with type 2 diabetes treated with diet and exercise alone or in combination with a stable dose of oral antidiabetic agents and/or insulin. This study included a 28-week open-label long-term extension in which patients in both treatment groups received BYDUREON 2 mg given subcutaneously once weekly after the 24-week controlled period.
In this trial, 88% of patients completed the assessment period. The mean age at study entry was 15.1 years (13% were 11 to 12 years old, 59% were 13 to 16 years old and 28% were older than 16 years). Approximately 42% of the patients were male, 43% were White, 4% were Asian, 31% were Black or African American, 6% were American Indian or Alaska Native, and 44% were of Hispanic or Latino ethnicity. . The mean body weight was 100.6 kg (67% were in ≥97 weight percentile group, 26% in ≥85 to <97 and 6%in ≥3 to <85), mean BMI was 36.4 kg/m² and the mean duration of diabetes was 2.3 years.
At baseline, mean HbA1c was 8.17%, 12.2% of patients were not treated with either oral antidiabetic medications or insulin, 40.2% were treated with one oral antidiabetic medication and 1.2% were treated with two oral antidiabetic medications. 79.3% of patients were receiving metformin and 1.2% were receiving sulfonylurea. Overall insulin usage was 46.3% (8.5% with insulin alone and 37.8% with insulin and one other oral antidiabetic medication).
The primary endpoint of the study was the change in HbA1c from baseline to Week 24.
Efficacy Results
BYDUREON was superior to placebo in reducing HbA1c (Table 11).
The mean changes from baseline to Week 24 for body weight were -0.17 kg with (SE 0.7) and +0.88 kg (SE 1.0) for BYDUREON and placebo, respectively.
Table 11: Results of 24-Week Trial of BYDUREON versus Placebo, Both alone or in Combination with Oral Antidiabetic Agents and/or Insulin in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus (Trial 8)
| BYDUREON 2 mg QW | Placebo QW | |
| Intent-to-Treat Population (N) | 58 | 24 |
| HbA1c (%) | ||
| Mean Baseline | 8.13 | 8.28 |
| Mean Change at Week 24 (SE)* | -0.25 (0.21) | 0.45 (0.29) |
| Difference from Placebo (95% CI) | -0.71† (-1.42, 0) | |
| HbA1c<7% | ||
| Percentage achieved goal at Week 24 | 31.0 | 8.3 |
| Fasting Plasma Glucose (mg/dL) | ||
| Mean Baseline | 165.2 | 170.5 |
| Mean Change at Week 24 (SE)* | -1.3 (8.1) | 16.2 (11.9) |
| * Adjusted LS means and treatment group difference(s) in the change from baseline values at Week 24 using a multiple imputation method that models a “wash-out” for patients having missing data who discontinued treatment. ANCOVA was used with treatment, region as fixed factors, and baseline HbA1c value as a covariate. SE – standard error. † p<0.05 ‡ Adjusted LS means in the change from baseline values at Week 24 using a multiple imputation method that models a “wash-out” for patients having missing data who discontinued treatment. ANCOVA was used with treatment, region, as fixed factors, and baseline FPG value as a covariate. |
||
BYDUREON®
(by-DUR-ee-on)
(exenatide) for extended-release injectable suspension,for subcutaneous use
Read this Medication Guide and the Instructions for Use that comes with BYDUREON before you start using it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or your treatment. If you have questions about BYDUREON after reading this information, ask your healthcare provider or pharmacist.
What is the most important information I should know about BYDUREON?
BYDUREON may cause serious side effects, including:
What is BYDUREON?
Who should not use BYDUREON?
Do not use BYDUREON if:
What should I tell my healthcare provider before using BYDUREON?
Before using BYDUREON, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. BYDUREON may affect the way some medicines work and some medicines may affect the way BYDUREON works.
Before using BYDUREON, talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking other medicines to treat diabetes, including insulin or sulfonylureas.
Especially tell your healthcare provider if you take warfarin.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use BYDUREON?
What are the possible side effects of BYDUREON?
BYDUREON may cause serious side effects, including:
Signs and symptoms of low blood sugar may include:
The most common side effects of BYDUREON may include nausea, diarrhea, headache, vomiting, constipation, itching at the injection site, a small bump (nodule) at the injection site, indigestion.
Talk to your healthcare provider about any side effect that bothers you or does not go away.
These are not all the possible side effects of BYDUREON. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Keep BYDUREON and all medicines out of the reach of children.
General information about the safe and effective use of BYDUREON.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BYDUREON for a condition for which it was not prescribed. Do not give your BYDUREON to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BYDUREON that is written for health professionals.
What are the ingredients in BYDUREON?
Contents of the powder:
Active ingredient: exenatide.
Inactive ingredients: polylactide-co-glycolide and sucrose.
Contents of liquid (diluent):
Inactive Ingredients: carboxymethylcellulose sodium, polysorbate 20, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, sodium chloride, water for injection. Sodium hydroxide may be added during manufacture of BYDUREON Pen for pH adjustment.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
BYDUREON®
(by-DUR-ee-on)
(exenatide)
for extended-release injectable suspension, for subcutaneous use
What is the most important information I should know about BYDUREON?
BYDUREON may cause serious side effects, including
What is BYDUREON?
Who should not use BYDUREON?
Do not use BYDUREON if:
What should I tell my healthcare provider before using BYDUREON?
Before using BYDUREON, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. BYDUREON may affect the way some medicines work and some medicines may affect the way BYDUREON works.
Before using BYDUREON, talk to your healthcare provider about low blood sugar and how to manage it.
Especially tell your healthcare provider if you take:
Know the medicines you take.
Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use BYDUREON?
What are the possible side effects of BYDUREON?
BYDUREON may cause serious side effects, including:
The most common side effects of BYDUREON may include nausea, diarrhea, headache, vomiting, constipation, itching at the injection site, a small bump (nodule) at the injection site, indigestion.
Nausea is most common when you first start using BYDUREON but decreases over time in most people as their body gets used to the medicine.
Talk to your healthcare provider about any side effect that bothers you or does not go away.
These are not all the possible side effects of BYDUREON. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
Keep BYDUREON and all medicines out of the reach of children.
General information about the safe and effective use of BYDUREON.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BYDUREON for a condition for which it was not prescribed. Do not give your BYDUREON to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BYDUREON that is written for health professionals.
What are the ingredients in BYDUREON?
Contents of the powder:
Active ingredient: exenatide.
Inactive ingredients: polylactide-co-glycolide and sucrose.
Contents of liquid (diluent):
Inactive Ingredients: carboxymethylcellulose sodium, polysorbate 20, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, sodium chloride, water for injection. Sodium hydroxide may be added during manufacture of BYDUREON Pen for pH adjustment.
BYDUREON is a registered trademark and BYETTA is a registered trademark of the AstraZeneca group of companies.
All other marks are the marks of their respective owners.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
INSTRUCTIONS FOR USE
BYDUREON®
(by-DUR-ee-on) Pen
(exenatide) for extended-release injectable suspension for subcutaneous use once-weekly
Figure A
 |
Before using Bydureon Pen, your healthcare provider should show you how to use it the right way.
Caregivers should help children with mixing and injecting BYDUREON.
Read the Instructions for Use before you start using Bydureon Pen and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Getting ready
Bydureon Pen is not for self-injection by people who are blind or cannot see well.
Supplies needed to give your Bydureon Pen injection (not all supplies are included):
 |
How should I store Bydureon?
Keep Bydureon Pen, and all medicines, out of the reach of children.
Step 1: Prepare your Bydureon Pen
Let your Pen come to room temperature.
 |
Wash your hands. Open the tray.
 |
Check the liquid in your Pen.
 |
Peel off the paper tab from the needle cover.
 |
Attach the needle to the Pen.
 |
Step 2: Mix your dose - Combine the medicine.
 |
Firmly tap your Pen to mix.
 |
Check the Bydureon mix.
Figure B
 |
Stop. Do Not proceed unless your medicine is mixed well.
To get your full dose the medicine must be mixed well. If it is not mixed well, tap longer and more firmly.
Check the Bydureon mix again.
Figure C
 |
If you have any questions or are not sure if your Bydureon is mixed well, call 1-800-236-9933 for help.
Step 3: Inject your dose
Important: After the medicine is mixed well, you must inject your dose right away. You cannot save it for later use.
Choose your injection site.
 |
Twist knob to release injection button.
 |
Remove the needle cover.
 |
Inject your Bydureon.
 |
Properly dispose of your used Pen.
 |
Common Questions and Answers:
1. How do I know that the Bydureon is mixed well?
The Bydureon is mixed well when the liquid looks cloudy from both sides of the window. You should not see any clumps in the liquid. It may help to hold your Pen up to the light to see in the window. If you see clumps of any size keep tapping your Pen firmly against the palm of your hand until mixed.
2. I am having trouble mixing my dose. What should I do?
Remember, before preparing your dose, leave your Pen out of the refrigerator for at least 15 minutes. This will let your Pen warm up to room temperature. It will be easier to mix Bydureon if your Pen is at room temperature.
Be sure you are holding your Pen at the end with the knob and the orange label. This will help you grip your Pen better and tap it more firmly against your palm.
It may also help to tap the mixing window on both sides against your palm. If you see any clumps, keep tapping.
3. After I mix Bydureon, how long can I wait before taking the injection?
You must inject your dose of Bydureon right after mixing it. If you do not inject your Bydureon right away, small clumps of medicine may form in your Pen and you may not get your full dose.
4. I am ready to inject my dose. What should I do if I see air bubbles in the Pen?
It is normal for air bubbles to be in your Pen. Bydureon is injected into your skin (subcutaneously). Air bubbles will not harm you or affect your dose with this type of injection.
5. What should I do if I cannot push the injection button all the way in when trying to inject my dose?
Check that you have fully screwed on the pen needle. Also be sure you twisted the knob until it stopped, the orange label disappeared, and the injection button appears.
If you still cannot push the button in, this may mean that the needle is clogged. Remove the needle from your skin and replace it with the spare needle from the carton. Review how to attach the needle. Then choose a different injection site and finish taking the injection.
If you still cannot push the button all the way in, remove the needle from your skin. Use a puncture-resistant container to throw away the pen with the needle still attached.
If you have problems giving your Bydureon Pen injection or have any questions call 1-800-236-9933 for more instructions.
6. How do I know if I injected my full dose?
To be sure you get your full dose, press the injection button with your thumb until you hear a “click”. After the “click”, continue to hold the needle in your skin for 10 seconds. This will allow enough time for you to get your full dose.
7. What if I do not have an FDA-cleared sharps disposal container?
Do not throw away (dispose of) loose needles and Pens in your household trash.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and Pens. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: https://www.fda.gov/safesharpsdisposal
 |
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
